MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Publishes Phase 1a Glioblastoma Data, Advances LP-184 Combination Therapy Toward Phase 1b/2a Trial

Lantern Pharma (NASDAQ: LTRN) and its wholly owned subsidiary, Starlight Therapeutics, announced the publication of Phase 1a clinical data for LP-184 (zirdafulven), also being developed as STAR-001, in patients with recurrent glioblastoma (“GBM”). Published in the October 2026 issue of Cancer Research Communications, the study evaluated 16 patients and found LP-184 was generally well tolerated, establishing a recommended expansion dose of 0.39 mg/kg. No objective radiographic responses were observed, although one patient remained clinically and radiographically stable for more than 22 months after enrollment. The findings also identified limited drug exposure in brain tumors, supporting further evaluation of LP-184 in combination with spironolactone, an FDA-approved drug that reduced the concentration of LP-184 needed to kill GBM cells by threefold to sixfold in preclinical models.

The company said the findings establish a dosing rationale for a planned Phase 1b/2a trial evaluating LP-184 plus spironolactone in patients experiencing their first GBM recurrence. The study, sponsored by Starlight Therapeutics under an FDA-cleared Investigational New Drug application, will assess safety, pharmacokinetics and objective response. The combination strategy was developed with support from Lantern’s RADR(R) AI platform and research collaborators at Johns Hopkins University. LP-184 has received FDA Fast Track Designation for GBM and triple-negative breast cancer, along with Orphan Drug Designations for certain central nervous system cancers.

To view the full press release, visit https://ibn.fm/qaLVQ

About Lantern Pharma

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify the patients most likely to benefit from Lantern’s therapies and to guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Publishes Phase 1a Glioblastoma Data, Advances LP-184 Combination Therapy Toward Phase 1b/2a Trial.